Is Vaxcyte Inc. (PCVX) positioned for future growth?

Vaxcyte Inc. (NASDAQ: PCVX) stock fell -1.80% on Monday to $50.79 against a previous-day closing price of $51.72. With 0.56 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $51.97 whereas the lowest price it dropped to was $49.99. The 52-week range on PCVX shows that it touched its highest point at $54.97 and its lowest point at $20.49 during that stretch. It currently has a 1-year price target of $66.14. Beta for the stock currently stands at 0.88.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCVX was down-trending over the past week, with a drop of -3.11%, but this was up by 7.11% over a month. Three-month performance dropped to -0.70% while six-month performance rose 35.12%. The stock gained 79.98% in the past year, while it has gained 5.92% so far this year. A look at the trailing 12-month EPS for PCVX yields -3.32 with Next year EPS estimates of -3.67. For the next quarter, that number is -0.84. This implies an EPS growth rate of -78.70% for this year and -15.80% for next year. EPS is expected to grow by 1.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -57.40%.

Float and Shares Shorts:

At present, 98.06 million PCVX shares are outstanding with a float of 89.01 million shares on hand for trading. On Aug 30, 2023, short shares totaled 7.55 million, which was 8.04% higher than short shares on Jul 30, 2023. In addition to Mr. Grant E. Pickering M.B.A. as the firm’s Co-Founder, CEO & Director, Mr. Andrew L. Guggenhime M.B.A. serves as its Pres & CFO.

Institutional Ownership:

Through their ownership of 92.33% of PCVX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 59.13% of PCVX, in contrast to 41.89% held by mutual funds. Shares owned by individuals account for 3.04%. As the largest shareholder in PCVX with 13.61% of the stake, Fidelity Management & Research Co holds 12,771,976 shares worth 12,771,976. A second-largest stockholder of PCVX, The Vanguard Group, Inc., holds 7,996,438 shares, controlling over 8.52% of the firm’s shares. RA Capital Management LP is the third largest shareholder in PCVX, holding 7,891,254 shares or 8.41% stake. With a 3.24% stake in PCVX, the American Funds Small Cap World Fu is the largest stakeholder. A total of 3,044,396 shares are owned by the mutual fund manager. The Vanguard Total Stock Market ETF, which owns about 2.85% of PCVX stock, is the second-largest Mutual Fund holder. It holds 2,673,190 shares valued at 138.79 million. Vanguard Health Care Fund holds 2.52% of the stake in PCVX, owning 2,365,953 shares worth 122.84 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, PCVX reported revenue of $0.00 and operating income of -$47.20M. The EBITDA in the recently reported quarter was -$44.62M and diluted EPS was -$0.80.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCVX since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PCVX analysts setting a high price target of $72.00 and a low target of $58.00, the average target price over the next 12 months is $66.14. Based on these targets, PCVX could surge 41.76% to reach the target high and rise by 14.2% to reach the target low. Reaching the average price target will result in a growth of 30.22% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded PCVX stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 24 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 306,285 while 52,360 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *